Objective. Inhibitory receptors are essential for the regulation of effector immune responses and may play critical roles in autoimmune diseases. We evaluated whether inhibitory receptor expression on T cells from patients with rheumatoid arthritis (RA) were correlated with immune activation, disease activity, and response to treatment, as well as whether inhibitory receptormediated pathways were functional.
Methods. Using flow cytometry, we performed extensive phenotypic and functional evaluation of CD4+ and CD8+ T cells from the blood and synovial fluid (SF) of RA patients ex vivo and after culture. The relationship of each parameter with the Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28-ESR) and response to treatment was examined.
Results. In RA patients with low levels of T cell activation, inhibitory receptor expression showed an inverse relationship with the DAS28-ESR. The frequency of T cells expressing multiple inhibitory receptors was reduced in untreated RA patients but returned to normal levels in treated patients. RA patients who responded to treatment showed an augmented frequency of inhibitory receptor-expressing T cells that correlated with reduced inflammatory cytokine production in comparison to nonresponders. Higher frequencies of effector and memory T cells that expressed multiple inhibitory receptors were seen in SF than in peripheral blood. Notably, inhibitory pathways were operative in blood and synovial T cells from all RA patients, although cells from nonresponder patients were less sensitive to inhibition.
Conclusion. Inhibitory receptor expression on T cells from RA patients is inversely correlated with effector T cell function and disease activity and may predict response to treatment. Furthermore, different inhibitory pathways are functional and cooperatively suppress synovial T cells, providing a rationale for new treatment strategies to regulate acute local inflammation.
Rheumatoid arthritis (RA) is a common chronic autoimmune disease characterized by persistent synovitis and systemic inflammation that frequently results in cartilage erosion and bone injury (1) . The current consensus is that RA development is attributable to genetic and environmental factors, as well as to abnormalities in innate and adaptive immunity (2) . Among the multifactorial events and multiple immune mediators that participate in RA, T cells are linked to RA pathogenesis at different levels, including initiation, progression, and perpetuation (3, 4) . Indeed, T cells expand and accumulate in the synovium, producing cytokines and mediators that sustain inflammation (5, 6) .
Considering that autoimmune diseases such as RA are characterized by persistent activation of T cells, pathways that regulate T cell expansion and function may modulate disease pathogenesis. Indeed, co-inhibitory pathways have been shown to affect self tolerance and autoimmunity (7) . Recently, inhibitory receptors, including programmed death 1 (PD-1), CTLA-4, CD160, B and T lymphocyte attenuator (BTLA), T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), T cell immunoreceptor with Ig and ITIM domains (TIGIT), and others, have emerged as key players in the control of T cell effector responses in chronic infections and cancer (8) . Inhibitory receptor expression is induced during the initial stages of T cell activation and is also associated with a terminal differentiation state termed "T cell exhaustion," which is characterized by the presence of multiple inhibitory receptors and poor functionality (9) .
The role of inhibitory receptors in RA and other autoimmune diseases is not well defined, and the few existing reports have focused on individual inhibitory pathways. In particular, the PD-1/programmed death ligand 1 (PD-L1) pathway has been shown to be involved in the regulation of local and peripheral T cell effector function (10) (11) (12) (13) . Recently, transcriptome studies in T cells from patients with different autoimmune diseases (including RA) linked gene expression patterns of T cell exhaustion to a favorable long-term clinical outcome characterized by fewer relapses (14) . Taken together, these findings suggest that studying the expression and role of inhibitory receptors on T cells from RA patients may provide useful information regarding the status of the ongoing inflammation and disease progression. Furthermore, these data will be helpful to establish whether manipulating inhibitory pathways could be beneficial in controlling the long-term course of the disease.
In this study, we evaluated the expression of activation markers and multiple inhibitory receptors in T cells from the blood and synovial fluid (SF) of RA patients. Furthermore, we determined the correlation between these markers, disease activity, and response to treatment. Finally, we established that the inhibitory pathways mediated by PD-1/PD-L1 and herpesvirus entry mediator (HVEM)/ CD160/BTLA are operative in the regulation of the proliferation and cytokine production of Tcells from RA patients.
PATIENTS AND METHODS
Patients. RA patients and healthy donors were recruited from the Rheumatology Service of Hospital Nacional de Cl ıni-cas. Patients were diagnosed as having RA according to the American College of Rheumatology/European League Against Rheumatism (EULAR) classification criteria (15) . Exclusion criteria included known or suspected ongoing infections or metabolic diseases for RA patients and any history of autoimmune disease or immunosuppressive therapy for healthy donors. For RA patients, the Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28-ESR) was assessed at the time of blood collection as previously described (16) . RA patients were divided into a remission group (DAS28-ESR <2.6) and an active disease group (DAS28-ESR ≥2.6). Patients were classified as untreated (never treated or not treated in the previous 6 months), treated with disease-modifying antirheumatic drugs (DMARDs; mainly methotrexate), or treated with antitumor necrosis factor (anti-TNF) agents with or without DMARDs (any TNF-blocking biologic agent plus mainly methotrexate). Response to treatment was defined according to the EULAR criteria (1, 17) . Patients who had a reduction in the DAS28-ESR of >1.2 after 3 months of treatment were considered responders, while patients who had a reduction in the DAS28-ESR of ≤1.2 after 3 months of treatment were considered nonresponders.
The study was approved by the Institutional Ethics Committee of the Hospital Nacional de Clínicas and performed according to the Declaration of Helsinki guidelines on studies with human subjects. All subjects provided written informed consent prior to any study procedure.
Specimens and cell separation. Peripheral blood (PB) was obtained from RA patients and healthy donors. The characteristics of the study subjects are shown in Table 1 . Serum samples were obtained for immunologic laboratory tests (details are * RA = rheumatoid arthritis; DAS28-ESR = Disease Activity Score in 28 joints using the erythrocyte sedimentation rate; DMARDs = diseasemodifying antirheumatic drugs; TNF = tumor necrosis factor; SF = synovial fluid; QD = quartile deviation; CRP = C-reactive protein; RF = rheumatoid factor; anti-CCP = anti-cyclic citrullinated peptide.
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ONOFRIO ET AL available upon request from the corresponding author). SF was collected from patients with active disease whenever possible. Peripheral blood mononuclear cells and SF were isolated by centrifugation in Ficoll-Hypaque density gradients (GE Healthcare Bio-Sciences) and cryopreserved until used.
Flow cytometric analysis and cell sorting. Flow cytometric analysis for the detection of surface molecules, intracellular cytokines, and intranuclear transcription factors was performed according to standard protocols (details are available upon request from the corresponding author).
In vitro cultures. Sorted CD4+ and CD8+ T cells (0.1 9 10 6 ) were resuspended in 1% phosphate buffered saline/fetal bovine serum, stained with 1 lM carboxyfluorescein succinimidyl ester (CFSE), and stimulated in 96-well flatbottomed plates (Costar) precoated overnight with 1 lg/ml anti-CD3 (OKT3; BioLegend) and 0.5 lg/ml anti-CD28 (CD28.2; BioLegend) in the presence or absence of soluble blocking anti-CD160 (CL1-R2; 2 lg/ml) (MBL), anti-PD-1 (J116; 10 lg/ml) (eBioscience), plate-bound agonistic HVEM: Fc (5 lg/ml; BioLegend), and/or PD-L1:Fc (5 lg/ml; R&D Systems). At the end of the stimulation (3 days for neutralization and 6 days for receptor ligation), cells were stimulated with phorbol myristate acetate/ionomycin to determine cytokine production. Proliferation was determined by CFSE dilution or detection of the proliferation marker Ki-67 (anti-Ki67 eFluor660; SolA15) (eBioscience). Fixable Viability Stain 780 was used to exclude dead cells.
The proliferation index was calculated as the ratio of the percentage of cell proliferation in cells stimulated with anti-CD3/anti-CD28 plus anti-CD160, HVEM:Fc, and/or PD-L1:Fc to the percentage of cell proliferation in cells stimulated with the mitogen only.
Statistical analysis. Statistical analysis was performed using GraphPad Prism 7 software. P values less than 0.05 were considered significant. The D'Agostino-Pearson omnibus normality test was initially performed to determine the distribution of the data sets. The specific tests used are indicated in the figure legends.
RESULTS
Different levels of inhibitory receptor expression in CD8+ T cells from RA patients according to T cell activation status. High expression of inhibitory receptors has been described at different stages of T cell life. Several inhibitory receptors are up-regulated in recently activated T cells that exhibit strong effector function (18) and may boost RA progression. However, inhibitory receptor expression is also a hallmark of terminally differentiated exhausted cells (19) , whose poor effector activity may be desirable in the context of RA. Therefore, evaluation of T cell activation status is an essential first step in understanding the significance of inhibitory receptor expression on T cells in RA.
As a measure of T cell activation, we determined the expression of CD69 on T cells from RA patients with active disease and healthy donors. Although CD4+ and CD8+ T cells were present in similar frequencies in PB from RA patients and healthy donors (data not shown), both T cell subsets showed an increased frequency of CD69+ cells in RA patients, indicating a high level of activation ( Figure 1A ). Of note, the highest frequencies of activated CD69+ cells were observed within the CD8+ T cells from RA patients, suggesting that up-regulation of activation markers on this population may be more sensitive than up-regulation on CD4+ T cells for denoting immune activation. Indeed, the frequency of CD69+ within CD8+, but not CD4+, T cells showed a significant linear correlation with disease activity determined by the DAS28-ESR ( Figure 1B) .
With regard to the frequencies of CD69+CD8+ cells, 2 clusters of patients with significantly different means were defined ( Figure 1C) . One cluster included patients with low frequencies of activated CD69+CD8+ T cells, who were considered to exhibit a low level of T cell activation. The other cluster comprised patients with more than 10% CD69+CD8+ T cells, considered a high level of T cell activation. Next, we evaluated the expression of 4 inhibitory receptors (CD160, PD-1, BTLA, and TIM-3) on CD8+ T cells from these clusters of patients with low or high T cell activation levels. (Details of the gating strategy are available upon request from the corresponding author.) Overall, CD8+ T cells from patients in the cluster with high levels of T cell activation showed increased expression of inhibitory receptors (particularly PD-1 and CD160) compared to those from patients in the cluster with low levels of T cell activation (results are available upon request from the corresponding author).
Notably, the frequency of CD8+ Tcells coexpressing 4 inhibitory receptors or different combinations of inhibitory receptors correlated positively with the percentage of CD69+CD8+ T cells in patients with high levels of T cell activation, indicating that high CD8+ T cell activation is linked to up-regulation of inhibitory receptors in RA ( Figure 1D and data not shown). In contrast, this correlation was not observed within the CD8+ T cells from patients with low levels of T cell activation or healthy donors ( Figure 1D ), yet these cells exhibited variable inhibitory receptor expression that may be linked to a cell dysfunction stage as a consequence of sustained chronic stimulation.
The frequency of inhibitory receptor-expressing T cells is reduced in untreated RA patients and increased upon successful treatment. We next evaluated whether inhibitory receptor expression on T cells from RA patients with active disease but low T cell activation may indicate cell dysfunction. To this end, we first determined the frequencies of CD8+ and CD4+ T cells that expressed multiple inhibitory receptors (PD-1, CD160, TIM-3, and BTLA) in healthy donors and RA patients with low T cell activation. RA patients were divided into groups according to treatment (untreated, treated with DMARDs, or treated with anti-TNF agents with or without DMARDs). CD8+ Tcells from untreated RA patients showed reduced frequencies of cells expressing multiple (2, 3, or 4) inhibitory receptors in comparison to those from healthy donors. Notably, the frequencies of inhibitory receptor-expressing CD8+ T cells tended to increase in patients treated with DMARDs and those treated with anti-TNF agents with or without DMARDs.
Statistical analysis confirmed that the percentage of CD8+ T cells expressing the 4 inhibitory receptors evaluated, as well as those expressing particular combinations of 3 inhibitory receptors, were significantly reduced in untreated RA patients (data are available upon request from the corresponding author). Given that the groups of treated patients included patients showing good, moderate, and bad responses to treatment according to the EULAR criteria, we performed a longitudinal analysis to determine the dynamic evolution of inhibitory receptor expression patterns according to clinical response after 3 months of treatment. Responders exhibited an increase in the frequency of CD8+ T cells that expressed 3 or 4 inhibitory receptors after 3 months of treatment in comparison to baseline. In contrast, no significant changes in the frequency of CD8+ T cells expressing different inhibitory receptor combinations were observed in nonresponders (results are available upon request from the corresponding author).
Since the frequencies of T cells expressing 3 or 4 inhibitory receptors were low and their study may not be feasible at the clinical level, we assessed whether changes in the expression of 1 or 2 inhibitory receptors could provide a more robust measure of therapy success. Of the 4 inhibitory receptors tested, we focused on CD160 and PD-1, which were expressed at higher frequencies. The percentage of CD8+ T cells expressing both PD-1 and CD160, but not those expressing only 1 inhibitory receptor, was significantly decreased in untreated RA patients in comparison to healthy donors and tended to increase in treated RA patients (Figure 2A) . Importantly, the increase in the frequency of CD8+ T cells expressing 1 or both of these inhibitory receptors correlated with treatment response (Figures 2B and C) . Responders exhibited a significantly augmented frequency of PD-1+CD160+ Figures 2B and C) . In contrast, nonresponders showed a reduction or no change in the frequency of CD8+ T cells expressing 1 or 2 inhibitory receptors and a significant increase in double-negative cells ( Figures 2B and C) . We also identified some combinations of inhibitory receptors expressed on CD4+ T cells (CD160+ and CD160+TIM-3+) that correlated with treatment success in RA (data not shown).
Association of reduced frequencies of inhibitory receptor-expressing CD8+ T cells with increased effector function and disease activity in RA patients with low immune activation. Next, we aimed to understand how changes in the frequencies of inhibitory receptorexpressing CD8+ T cells observed in RA patients undergoing treatment influenced effector cytokine production upon T cell activation. We determined that the frequency of CD8+ T cells secreting TNF, interferon-c (IFNc), or interleukin-2 (IL-2) in responders was as low as that in healthy donors. In contrast, nonresponders who showed no changes in inhibitory receptor expression upon treatment exhibited significantly increased percentages of CD8+ T cells producing effector cytokines compared to responders and healthy donors ( Figure 3A) . Also, CD4+ T cells from nonresponders contained a significantly augmented frequency of cells producing effector cytokines, such as TNF, IFNc, IL-2, and IL-17, compared to those from responders or healthy donors ( Figure 3B) .
Considering that the frequency of inhibitory receptor-expressing T cells in RA patients was inversely associated with the production of effector cytokines, we speculated that inhibitory receptor expression on T cells could also correlate with a more comprehensive clinical parameter such as disease activity. To test this, we evaluated whether the frequencies of CD8+ and CD4+ T cells expressing different inhibitory receptor combinations correlated with the DAS28-ESR in the total cohort of patients involved in this study, including A and B, Frequency of cells producing the indicated effector cytokines within peripheral CD8+ (A) and CD4+ (B) T cell gates in healthy donors (HD), patients with rheumatoid arthritis (RA) who responded to therapy (rRA), and patients with RA who did not respond to therapy (nrRA). Symbols represent individual subjects; horizontal and vertical lines show the mean AE SD. TNF = tumor necrosis factor; IFNc = interferon-c; IL-2 = interleukin-2. C, Correlations between the frequencies of peripheral CD8+ T cells expressing programmed death 1 (PD-1) and CD160 together, PD-1 alone, or CD160 alone and the Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28-ESR) in RA patients at baseline (T0), after 3 months of treatment (T3), and after 6 months of treatment (T6). Symbols represent individual patients; dotted lines show the 95% confidence interval. P values were determined by one-way analysis of variance followed by Bonferroni post hoc test in A and B. Pearson's correlation coefficient and P values are shown in C. untreated patients, patients treated for 3 months, and patients treated for 6 months. This analysis showed a negative correlation between the DAS28-ESR and the frequencies of CD8+ T cells expressing PD-1 and CD160 together and individually ( Figure 3C ). Furthermore, similar negative correlations were observed between the DAS28-ESR and CD8+ T cells expressing 4 inhibitory receptors and particular combinations of 3 inhibitory receptors (data are available upon request from the corresponding author). This negative correlation was also found for some patterns of inhibitory receptor expression on CD4+ T cells (data are available upon request from the corresponding author).
Taken together, our data indicate that in patients exhibiting low levels of T cell activation, a reduced frequency of inhibitory receptor-expressing CD8+ and CD4+ T cells after treatment significantly correlated with increased production of effector inflammatory cytokines and more severe disease activity.
SF effector CD8+ T cells exhibit a potent cytokineproducing function that is inversely correlated with inhibitory receptor expression. To establish the biologic events occurring at sites of inflammation during RA, we collected SF and evaluated the composition of the immune infiltrate in comparison to the paired PB samples. The CD45+ cell SF infiltrate was composed of~20% lymphocytes, while the rest included mainly neutrophils and to a minor extent monocytes (data are available upon request from the corresponding author). Frequencies of CD8+ and CD4+ T cells were similar between paired SF and PB samples from RA patients (data are available upon request from the corresponding author). Similar to the findings of previous studies (20) , we observed that central and effector memory subsets were significantly increased, while naive and terminal effector subsets were significantly reduced, within CD8+ and CD4+ T cells from SF in comparison to the paired PB samples (data are available upon request from the corresponding author). Interestingly, after 3 months of treatment, responders but not nonresponders showed significantly increased frequencies of CD8+ and CD4+ Tcells with the terminal effector phenotype (data are available upon request from the corresponding author).
Next, we performed functional studies and determined that synovial CD8+ T cells produced higher levels of TNF, IFNc, and IL-2 than their PB counterparts and that there were significant positive correlations between the frequencies of cytokine-producing CD8+ T cells from SF and the paired PB samples ( Figure 4A ). Detailed phenotype studies showed that the highly activated effector CD8+ T cells from SF were enriched in cells expressing BTLA, CD160, PD-1, and TIM-3 and that the percentage of synovial CD8+ T cells expressing 4 inhibitory receptors was positively correlated with that in the paired PB samples ( Figure 4B and data available upon request from the corresponding author). As expected given its inflammatory nature, SF exhibited overall increased frequencies of inhibitory receptor-expressing and cytokine-producing T cells in comparison to paired PB samples. Importantly, although the frequency of inhibitory receptor-expressing CD8+ T cells was low in PB, there was a significant positive correlation with that in the paired SF. We also determined that synovial CD8+ Tcells showed a high percentage of cells exhibiting the phenotype Eomes+PD-1+ ( Figure 4C ), which has previously been associated with poor effector function (19) .
We next evaluated the correlation of inhibitory receptor expression and effector cytokine production within SF and observed that, consistent with the results obtained in PB for responders versus nonresponders (Figure 3A) , the frequency of inhibitory receptor-expressing synovial CD8+ T cells inversely correlated with the percentage of synovial cells producing effector cytokines ( Figure 4D ). Therefore, even in the complex environment of an inflammatory site such as the synovium, a higher expression of inhibitory receptors within the CD8+ T cell population is linked to poorer effector responses.
Within the CD4+ T cell population, only IFNcand IL-17-producing cells were increased in SF versus the paired PB samples, but there was no correlation between the frequencies of these cells in SF and PB (data are available upon request from the corresponding author). Furthermore, although a high percentage of synovial CD4+ T cells expressed multiple inhibitory receptors, there was no correlation with the paired PB samples or the cytokine-producing population in SF (data are available upon request from the corresponding author).
Role of inhibitory pathways in regulating proliferation and cytokine production by synovial and peripheral T cells from RA patients. We investigated whether inhibitory receptors are functional in T cells from RA patients and could be exploited to control the ongoing inflammatory response. We developed an assay to evaluate how T cell activation was affected by ligation of CD160/BTLA and/or PD-1 using HVEM:Fc and/or PD-L1:Fc proteins, respectively. HVEM:Fc significantly reduced the proliferation of CD8+ and CD4+ T cells from healthy donors as well as responders and nonresponders, while PD-L1:Fc significantly decreased the proliferation of CD8+ T cells from responders only and CD4+ T cells from responders and nonresponders. Notably, the combination of HVEM: Fc and PD-L1:Fc inhibited the proliferation of all samples assayed ( Figure 5A ).
Next, we determined that the CD160/BTLA and PD-1 pathways were also operative in highly activated synovial CD8+ and CD4+ T cells ( Figure 5B) . Importantly, comparative analysis of the effect observed in Figures 5A and B showed that the combination of HVEM:Fc and PD-L1:Fc acts synergistically to suppress T cell proliferation, particularly in peripheral CD4+ and CD8+ T cells from responders and in synovial T cells ( Figure 5C ). Agonism of the CD160/BTLA and PD-1 pathways also decreased the frequency of synovial CD8+, but not CD4+, T cells that produced effector cytokines ( Figure 5D ). Engagement of inhibitory receptors expressed on peripheral T cells also inhibited effector cytokine production to a variable extent (data are available upon request from the corresponding author). Of note, stronger inhibitory receptor ligation induced by higher agonist concentrations led to deletion of the activated Tcells (data not shown).
We then evaluated whether T cell-T cell interactions triggered CD160-and PD-1-mediated pathways on T cells from healthy donors and RA patients. We first determined that CD8+ and CD4+ T cells from healthy donors and RA patients expressed HVEM. Of note, the frequencies of HVEM-expressing Tcells were significantly reduced in untreated RA patients compared to healthy donors and were increased to normal levels in treated patients (data are available upon request from the corresponding author). Blockade of CD160/HVEM engagement by an anti-CD160 antibody resulted in higher proliferation of all of the samples assayed except for CD4+ T cells from nonresponders (data are available upon request from the corresponding author). Inhibition of the CD160 pathway also increased the frequency of cytokine-producing cells within CD8+ and CD4+ T cells from healthy donors and responders but showed a limited effect in T cells from nonresponders (data are available upon request from the corresponding author).
In contrast, and despite the fact that a variable frequency of T cells from healthy donors and RA patients expressed PD-L1 (unpublished observations), blockade of PD-1/PD-L1 engagement showed no effect in proliferation or cytokine production in cultures including only Tcells (data not shown).
DISCUSSION
Previous studies have shown that polymorphisms in the PD-1, CTLA-4, and CD244 genes are associated with a greater susceptibility to RA and other autoimmune diseases (10, 21, 22) , while the CD160 gene is included within gene hubs significantly associated with RA (23). Furthermore, most patients receiving checkpoint blockade as immunotherapy during cancer develop immune-related adverse events that involve most organ systems, including the joints (24, 25) . Maybe more significant from a clinical point of view, recent data indicate that inhibitory receptor-mediated pathways, which negatively interfere with T cell activation and function, specifically protect against a relapsing course in multiple autoimmune diseases (14) . In this context, the regulation of the extent and duration of a pathologic immune response by inhibitory receptor-mediated pathways may emerge as a relevant mechanism dictating the clinical course of the disease once it is established (26) . We focused on RA and determined that patients showing high levels of T cell activation defined by high expression of CD69 on peripheral CD8+ T cells exhibited an increased frequency of inhibitory receptor-expressing T cells, consistent with the fact that inhibitory receptor expression is induced by Tcell activation (18) .
Increased expression of TIGIT on the surface of CD4+ T cells was recently shown to be associated with a higher DAS28 and increased evidence of inflammation in RA patients (27) . Given that T cell activation results in the transient up-regulation of some inhibitory receptors (18) , it is likely that the TIGIT+ T cells identified by Luo and colleagues (27) include activated T cells with increased potential to proliferate and produce effector cytokines. In contrast, our results indicated that the inhibitory receptor-expressing CD8+ T cells from RA patients with low levels of T cell activation are more likely undergoing terminal differentiation (i.e., exhaustion), a T cell differentiation stage associated with sustained expression of multiple inhibitory receptors (28) . Interestingly, in these patients, the frequency of CD8+ T cells expressing multiple inhibitory receptors as well as those showing a phenotype compatible with terminal effector memory RA cells increased upon successful treatment and inversely correlated with T cell effector function and clinical disease activity. These data highlight that expression of activation/differentiation markers and multiple inhibitory receptors in T cells could be useful markers of prognosis and treatment success in RA.
Recently, induction of T cell exhaustion has been suggested as a novel therapeutic approach for autoimmune diseases (26) . In support of this suggestion, some studies have demonstrated that agonism of the PD-1 pathway regulated peripheral and synovial Tcell responses during experimental and human RA (11, 12) . However, in many patients, RA was resistant to PD-1-mediated inhibition, likely as a consequence of the presence of a decoy soluble PD-1 in the inflammatory environment (10, 13) . Our results are consistent with these findings and further extend them as we showed that responsiveness to PD-1 ligation is conserved only in RA patients who exhibited a good response to therapy. Furthermore, we determined that the PD-1 inhibitory pathway is not triggered by T cell-T cell interactions and likely requires the presence of other PD-L1+ immune cells such as monocytes.
We also addressed the role of additional inhibitory receptors such as CD160 and BTLA since both belong to a bidirectional signaling network that critically modulates T cell biology. Within this network, HVEM (a member of the TNF receptor superfamily expressed on dendritic cells, regulatory cells, or T cells) is able to ligate both BTLA and CD160 on T cells to transduce inhibitory signals. These negative signals may be counterbalanced by costimulatory signals delivered after direct engagement of HVEM on T cells by LIGHT expressed on dendritic cells or other T cells (29) . During different biologic conditions (homeostasis, infection, autoimmunity, or cancer), there may be a predominance of negative over positive signaling or vice versa as a result of differences in ligand/receptor affinity and/or the differential expression pattern of these molecules on cell types at different stages of cell differentiation (30) . In this regard, we determined that agonism of the inhibitory receptors CD160 and BTLA suppressed proliferation and/or inflammatory cytokine production by peripheral and synovial CD4+ and CD8+ T cells from most RA patients. In addition, we also demonstrated that at least the CD160-mediated inhibitory signal can be triggered by T cell-T cell interactions. More importantly, we showed that a combination of PD-1 and CD160/BTLA ligands exerted a synergistic inhibitory effect on T cells from all RA patients, including those with poor response to regular treatments.
Taken together, our data and the findings of previous studies highlight the fact that inhibitory receptors play critical roles in the modulation of the ongoing inflammatory response and immunopathology during RA. Triggering these inhibitory pathways at a local or systemic level may emerge as a rational approach for the treatment of refractory RA.
